Inetetamab combined with pyrotinib and oral vinorelbine for patients with human epidermal growth factor receptor 2 positive advanced breast cancer: A single-arm phase 2 clinical trial-Reference-Cited by-同舟云学术

Inetetamab combined with pyrotinib and oral vinorelbine for patients with human epidermal growth factor receptor 2 positive advanced breast cancer: A single-arm phase 2 clinical trial

Published:2024-01 Issue:1 Volume:2 Page:31-37
ISSN:2949-7132
Container-title:Cancer Pathogenesis and Therapy
language:en
Short-container-title:Cancer Pathogenesis and Therapy

Author:

Jin Nan,Xu Yi,Wang Siqi,Sun Chunxiao,Yan Xueqi,Yang Fan,Liang Yan,Chen Weiwei,Huang Xiang^ORCID

Publisher

Elsevier BV

Reference35 articles.

1. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Sung;CA A Cancer J Clin,2021

2. Breast cancer;Harbeck;Nat Rev Dis Prim,2019

3. HER2-positive breast cancer;Loibl;Lancet,2017

4. Breast cancer treatment: a review;Waks;JAMA,2019

5. Aiming at a tailored cure for ERBB2-positive metastatic breast cancer: a review;Tarantino;JAMA Oncol,2022

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Neoadjuvant inetetamab and pertuzumab with taxanes and carboplatin (TCbIP) In locally advanced HER2-positive breast cancer: a prospective cohort study with propensity-matched analysis;BMC Cancer;2024-07-22

2. Connecting scientists and oncologists for advances;Cancer Pathogenesis and Therapy;2024-07

3. Phase 1b trial of anti‐HER2 antibody inetetamab and pan‐HER inhibitor pyrotinib in HER2‐positive advanced lung cancer;MedComm;2024-04-29

4. Inetetamab-based therapy in real-world treatment patterns with HER2-positive advanced breast cancer patients: a retrospective single-center study;Therapeutic Advances in Medical Oncology;2024-01